• Biopharmaceuticals:FREYR Angel Round ProjectBeijing Yanming Biotechnology Co., Ltd.Raised hundreds of millions of yuan in A+ round financing,FREES FUND Continues to Increase Investment; Peakview Capital A Round ProjectXtalPiListed on the Main Board of the Hong Kong Stock Exchange; PeakView Angel Round ProjectMETiS TechBioRaised $100 Million in Series C Financing; Fengrui Angel Round ProjectXinyong (Beijing) Technology Co., Ltd.Raised tens of millions of RMB in Series A financing,FREES FUND Followed the Investment; Peakview Angel Round ProjectCaribioSuccessfully completed a new round of financing; Peak Ventures seed projectSuzhou Weibang Zhendian Optoelectronic Technology Co., Ltd.Raised nearly 100 million RMB in A+ round financing,FreeS Fund Over-Subscribed Follow-on Investment。

  
  

• Soft and Hard Technology:Fengrui Angel Round ProjectPhoton-basedRaised nearly 100 million yuan in angel+ round series financing,FREES FUND Follow-up Investment; Peak Fortune Angel Round ProjectZhuji DynamicsCompleted a new round of strategic financing;Hangkai MicroelectronicsRaised tens of millions of yuan in angel round financing,FREES FUND Exclusive Investment。

  
  

• Consumer and TMT: IceWhale TechnologyRaised tens of millions of RMB in Pre-A+ round financing,FREES FUND Led the Investment。

  
  

(This summary of financing information is limited to those publicly disclosed from March 2024 to June 2024, sorted by the time of public release of corporate financing news.)

▲Image Source: Guang Benwei Technology

/ Investor Says /

Frees Fund has long been optimistic and continues to invest.Photonics FieldLight, as a carrier with both information and energy transmission functions, has broad application prospects in the fields of processing, imaging, and computing. In terms of computing, as the continuous demand for computational power grows, electric chips are gradually approaching their physical limits.Optical ComputingIt is expected to excel in the field of high-speed computing, especially in artificial intelligence.Break Through the Limitations of Traditional Computing Chips, becomingNext-Generation Computing Foundation Technology。

PhotonBit demonstrates great application potential in fields such as optical computing and communication through the research, development, and application of novel optical modulation methods. Amidst the major trend of "light advancing, copper retreating," we believe PhotonBit can becomeCore Enterprise of Full-Optical Information System。

/ Company Details /

As the infrastructure of artificial intelligence, computing power is still in a situation of supply being less than demand.The computing power gap continues to widen.。In addition to GPUs, the industry is also urgently looking for otherComputing Power Alternative Solutions——Optical chips are one of them. Compared with the traditional optical computing route,"Light-Based Approach" Adopts PCM+Crossbar Path with Stronger Advantages, achieving a higher level of integration and lower power consumption.

In terms of products, "Light Base"OPU (Optical Processing Unit) ChipMaintaining rapid iteration, it has currently been completed.Three-time Flow ChipNotably, the interfaces and instruction sets in the "light-based" product form remain highly compatible with existing data centers. Therefore, this chip will alsoCapable of adapting to large models available on the market。

Regarding the founding team, the founder of "Guang Benwei" hasBoth are post-95s.. Among them, the co-founder of the companyXiong YinjiangYesMaster of Computational Science, University of Chicago, with development and market experience in Google's AI framework TensorFlow, responsible for team management and business operations; Co-founderCheng Tangsheng studied under the world's leading expert in "phase-change material optical computing.", Professor of Materials at Oxford University, Fellow of the Royal Academy of EngineeringHarish Bhaskaran, responsible for R&D breakthroughs and engineering implementation, the latter also isChief Advisor of the Company。

Other core R&D team members have previously worked at Hesai Photonics, Qualcomm, ESWIN, and Zheku, all of whom are leaders in their respective fields, with extensive experience in R&D and industrial implementation. (For more details, see the report.)【36Kr Pro】Developing Photonic Computing Chip OPU, "Light Base" Completes Nearly 100 Million Angel+ Round of Financing | 36Kr Exclusive）

FREYR Angel Round ProjectZhuji DynamicsCompleted a new round of strategic financing.

/ Investor Says /

General Intelligent Robot, includingHumanoid, Quadruped, Wheeledin different forms, are carriers ofThe Carrier of AI and Physical World Perception Interaction。The Integration of AGI Intelligence and Humanoid Robots, advancing the explosion of technology research and development and commercial expectations. Humanoid robots are not a simple combination of operation and movement; they requireAI and Ontology Technology SynergyBuild a comprehensiveHumanoid Foundation Large Model。

The ZHUJI Dynamics team has a deep underlying accumulation in AI combined with motion control technology and is advancing robotics technology fromIndependent perception, decision-making, and controlToOrganically Integrated Underlying Large ModelDirection of development. We look forward to seeing the ZhiJi Dynamics team always at the forefront of the industry, driving the continuous advancement of general robot technology and products, and crossing the commercialization tipping point in the near future.

/ Company Details /

Zhuji Dynamics is aUniversal Robots, Focusing onAdvanced Software and HardwareResearch and development and manufacturing, coveringFull-size humanoid robots, four-wheeled legged robots, bipedal robotsAnd related solutions, with落地 applications focused on B2B and B2C fields such as intelligent manufacturing, industrial inspection, logistics distribution, special operations, and home services.(For details, see the report[Investment Community] General Robotics Startup "Zhuji Power" Completes New Round of Strategic Financing）

/ Content Recommendation /

Fengrui Angel Round ProjectBeijing Yanming Biotechnology Co., Ltd.Raised hundreds of millions of yuan in A+ round financing,FREES FUND Continues to Increase Investment。

/ Investor Says /

Since its establishment, Beijing Yanming Biotechnology Co., Ltd. has relied on solid and efficient scientific achievements and a clear disease transformation strategy.Natural ImmunityAndTumor ImmunologyField Rapidly EstablishedGlobal Leading Scientific Platform Status. In multiple new and highly challenging targets and projects, Beijing Yanming Biotechnology Co., Ltd. has made breakthrough progress. To address unresolved medical challenges worldwide, its scientific research achievements hold immeasurable significance for human health and enormous commercial value. Frees Fund will remain steadfast.Support China's Original Innovation, and firmly support Beijing Yanming Biotechnology Co., Ltd. in writing a new chapter of pharmaceutical innovation in China.

/ Company Details /

Beijing Yanming Biotechnology Co., Ltd. was founded byAcademician Shao FengAndDr. Deng TianjingCo-founded, the scientific foundation is based on Academician Feng Shao's work inNatural Immunity and PyroptosisFieldWorld-leading biological discoveries, choose inInflammationAndTumorThe main research focus is on critical medical issues in the field that have yet to be resolved, with an aim to develop treatments for inflammation and tumors.Revolutionary Innovative Drug, determined to become a company based on the scientific discoveries of Chinese scientists and driven by original innovation.A Leading Chinese Biotechnology Company on a Global Scale, and extend the benefits of China's original innovative achievements to patients with inflammation and tumors worldwide.

Beijing Yanming Biotechnology Co., Ltd. has established a group company structure, with its headquarters and small molecule immune modulation new drug R&D center in Beijing, the biologic immune modulation new drug R&D center in Shanghai, and the BD and clinical center in the United States. Beijing Yanming Biotechnology Co., Ltd. is currentlyThe most cutting-edge scientific platform company in the field of innate immunity, by developing small molecules and biomolecules targeting multiple new targets related to inflammasomes or pyroptosis, upregulating or downregulating the body's inflammatory response levels for treatmentDiseases of excessive immune activation such as cytokine storm, inflammatory bowel disease, and sepsisProvides new possibilities for treatment.In addition, pyroptosis of tumor cells can be induced to recruit and activate immune cells, enhancing the recognition of tumor cells by immune cells, thereby killing tumor cells and addressing the current challenge of low response rates in tumor immunotherapy.

The company currently hasTen R&D projects with entirely new mechanisms and novel targets,All areWorld's First, multiple projects have made breakthrough progress. Among them, the ALPK1 agonist PTT-936 was approved by the U.S. Food and Drug Administration (FDA) in November 2023 and is now undergoing clinical research in the United States; several innate immune inhibitors and pyroptosis inhibitor projects have identified PCC and are currently conducting preclinical research and development work. (For more details, see the report.)[Pyrotech] Beijing Yanming Biotechnology Co., Ltd. Announces Completion of Hundreds of Millions of RMB in Series A+ Financing）

▲ Image Source:Xinyong (Beijing) Technology Co., Ltd. Official Website

FREYR Angel Round ProjectXinyong (Beijing) Technology Co., Ltd.Raised tens of millions of RMB in Series A financing,FREES FUND Followed the Investment。

/ Investor Says /

AchieveContinuous, Accurate, and Non-Invasive Blood Pressure MonitoringYesA Holy Grail in the Field of Medical Measurement, which requires disruptive innovation and design. Xinyong integrates pressure and photoelectric sensors in hardware, and combines hemodynamics and machine learning in algorithms, which has been achieved.Clinical Precision in Wearable Blood Pressure MeasurementXinyong TeamShowcasedAn extremely strong ability to solve difficult problems in the field of medical-engineering integration, combat effectiveness and business acumen.

We look forward to the prompt release of a watch that is as accurate as an electronic sphygmomanometer and can measure pressure in real time, thereby achievingBetter Blood Pressure Management, Fewer Cardiovascular and Cerebrovascular Diseases。

/ Company Details /

Xinyong (Beijing) Technology Co., Ltd. was founded in 2020, co-founderLi YibinGraduated fromDepartment of Microelectronics, Tsinghua University, with over 10 years of in-depth experience in blood pressure monitoring; Co-founderWei YaoguangLead the development of hemodynamic models, signal compensation tuning, and other algorithms; Founding PartnerWen WuMainly drive sensor design, process development, supply chain, and system hardware development, and lead project execution, etc.

The continuous acquisition technology for current blood glucose (CGM), blood oxygen, and other vital sign indicators has become relatively mature and has created a considerable market volume. However,Blood PressureAs an equally important physiological indicator, it is constrained by the lack of an ideal technical solution and remains so currently.Difficult to achieve continuous monitoringXinyong Technology attempts to analyze blood pressure signals through a composite sensor array, combined with a fluid dynamics algorithm model, and use AI for compensation and correction to achieve...Continuous, Seamless Blood Pressure Data Collection. (For details, see the report【36Kr Pro】Xinyong Technology Raises Tens of Millions in Series A Funding, Upgrades and Mass Produces Continuous Blood Pressure Monitoring Products | Early Morning News）

IceWhale TechRaised tens of millions of RMB in Pre-A+ round financing,FREES FUND Led the Investment。

/ Investor Says /

The NAS products of Ice Whale Technology from contentCreators, Small and Medium-sized Studiosand other细分professional groups切入, the futureHas the potential to "break through"。

In the short term, the large number of creators fostered by long and short video platforms need storage products that can simultaneously offer ultra-large storage, collaborative office capabilities, and ultra-fast transmission—NAS products combine these functions. In the long term, with the popularization of localized AI deployment, smart home systems, and household intelligent robots,Combined with privatized data, PossessA certain amount of computational power, SimultaneouslyWith Gateway FunctionTheNAS, which is a very suitable AI terminal device.

Ice Whale TechnologyFounder LaurenYesProduct Manager Pursuing Perfection, with prior experience in defining well-known products within the industry, while also excelling at capturing subtle consumer needs across different scenarios. In terms of products, fromOpen-source System CasaOSToBrand New ZimaOSOver the past two years, IceWhale Technology has withstood market tests, with its operating system installed more than 500,000 times. On this basis, IceWhale has gathered a group of technology enthusiasts, and developers have actively participated in the NAS application ecosystem.ZimaCube has made specific adaptations., to meet the transmission and collaboration needs of content creators. Behind this is the team's understanding and control of user needs. In addition, ZimaCube alsoIntegrated hardware and software capabilities of localized AI Agent, and will further explore the localized deployment of AI in collaboration with developers and Chinese chip manufacturers.

/ Company Details /

/ Related Content /

Fengrui A Round ProjectXtalPiListed on the Main Board of the Hong Kong Stock Exchange.

/ Investor Says /

Congratulations on the successful listing of XtalPi! As one of the earliest teams able to leverage computation and AI to enhance the efficiency of drug discovery, the founding team of XtalPi...TeamAlways Firmly Believe in the Future of AI Drug Development. It is precisely this strong determination and the ability to continuously deliver results that has won XtalPi the support of many customers and investors.

Equally important is XtalPi's breakthrough in the direction of dataization. Having both experienced the era of AI pharmaceuticals 1.0, XtalPi and Fengrui both believe thatThe Bottleneck of AI Drug Development Lies in DataficationWithout high-quality data, even the best models cannot be implemented. XtalPi therefore strongly promotesIntroducing Robots into Wet LabsThe process has deployed hundreds of robots of various models for chemical experiments in Shenzhen and Shanghai, creating aNew Digital Infrastructure; Based on this, XtalPi has gradually formedQuantum Computing + AI + RoboticsThe technical landscape has successfully caught the train of the AI pharmaceuticals 2.0 era.

In addition, XtalPi has also made extensive explorations in commercial implementation. In addition toThe Entire Process of Drug Discovery and ResearchThe different modules provide solutions, XtalPi inSmall molecules, large molecules, roboticsAll three areas of the business have seen steady growth and have gained recognition from MNCs (multinational corporations), well-known pharmaceutical companies in China, and synthetic biology enterprises.

Gen AI (Generative AI) is the greatest technological breakthrough of this era, andAI + Biomedical is one of the most important application directions of Gen AI.Introducing embodied intelligence robots into biochemical laboratories and applying generative AI to drug research and development, we look forward to seeing XtalPi continue.Empower companies in the ecosystem, continuously bringingNew Drugs and New Materials。

Congratulations to XtalPi! Standing at the new starting point of Hong Kong Stock Exchange's 18C, XtalPi is expected to continueDo the Right Thing, Not the Easy Thing, becomingAn Excellent Company that Values Both Social and Commercial Value。

/ Company Details /

QuantumPharm Inc. (“Company” or “XtalPi”; Stock Code: 2228.HK)Three Postdoctoral Physicists from MITFounded in 2015, it is a basedQuantum Physics, andArtificial IntelligenceEmpower andRobotDriven innovative R&D platform.

The company adopts a method based onFirst-principles calculations in quantum physics, artificial intelligence, high-performance cloud computingAndScalable and Standardized Robotic Automation Combinedin the field of pharmaceuticals and materials science (including agrotechnology, energy, new chemicals, and cosmetics), providing R&D solutions and services in drug and materials science to global and domestic companies. (For more details, see the report.)【XtalPi】XtalPi Listed on the Main Board of HKEX, AI + Robotics Create the First 18C Stock）

/ Content Recommendation /

▲Structure of Small Nucleic Acid Conjugates

Fengrui Angel Round ProjectCaribioSuccessfully completed a new round of financing.

/ Investor Says /

Ideal drugs often have a high therapeutic index and low dosing requirements."Targeted Delivery"Therefore, it has received widespread attention in current drug research and development. Since its establishment, Caregen Bioscience has been...Molecular CouplingAndDelivery SystemSignificant progress has been made in the construction of. Focusing on solvingExtracellular Delivery of Small Nucleic Acid DrugsAndBlood-Brain Barrier Drug DeliveryThese two industry challenges, Ji Jin Bio was the first in China to develop antibody-small nucleic acid conjugate drugs and has built a patentedBlood-Brain Polypeptide Technology PlatformWe look forward to the continuous validation and breakthroughs of CagenBio's innovative drugs in clinical trials.

/ Company Details /

Cajal Bio is a company engaged inBiotech Companies for Innovative Drug Development, founded in January 2022, inAntibody-Small Nucleic Acid Conjugate DrugsAndBrain DeliveryTwo core technology fields, withFull independent intellectual property rightsChajin Biotech has a 600-square-meter R&D laboratory in Zhangjiang and a wholly-owned subsidiary in Suzhou. The company adheres to a flat, high signal (R&D) to noise (management) ratio operational model, with its first pipeline expected to enter clinical trials in 2024.

Chariot Biotech focuses onDrug Conjugation and Delivery Technology, pioneered the development of antibody-small nucleic acid conjugate drugs in China, filling the gap in non-hepatic delivery of nucleic acid drugs, and providing a solution for a long-standing issue."Patients with neuromuscular diseases suffering from 'lack of medical resources and medicines'"Bring hope. In addition, theBrain-Targeting Peptide-Brainferry Platform, with the opportunity to assist including small nucleic acids在内的Large Molecule Drugs Break Through the Blood-Brain Barrier, for a broader range of neurodegenerative diseases, such asAlzheimer's Disease, Parkinson's DiseaseBring about a revolution in treatment. (For details, see the report.)【CarryBio】CarryBio Completes New Round of Financing, Continuing to Lead a New Chapter in Drug Delivery）

FREYR Angel Round ProjectMETiS TechBioRaised $100 Million in Series C Financing.

/ Investor Says /

/ Company Details /

METiS TechBio (METiS Pharmaceuticals) was founded in 2020 and is a company focused onAI-Driven Drug Delivery and Drug DiscoveryTheInnovative Biotechnology Company。

METiS TechBio aims to drive the R&D of innovative drugs more efficiently and precisely by combining cutting-edge technologies such as new AI, machine learning, and quantitative simulations with drug development, achieving greater effectiveness.Innovative Delivery Material Design、Candidate Drug Selection and Formulation Design、"Programmable Nucleic Acid Drugs" DevelopmentAndNucleic Acid Delivery Design, bringing revolutionary drugs to patients worldwide and addressing unmet clinical needs. (For more details, see the report.)[METiS TechBio] Focuses on "AI + Drug Delivery," METiS TechBio Completes $100 Million Series C Financing）

Fengrui Seed Round ProjectSuzhou Weibang Zhendian Optoelectronic Technology Co., Ltd.Raised nearly 100 million RMB in A+ round financing,FREES FUND Overweight Follow-up Investment。

/ Investor Says /

Traditional optical imaging has approached its physical limits,Optical Manipulation and Computational OpticsBecome a new development trend.

Suzhou Weibang Zhendian Optoelectronic Technology Co., Ltd.Stimulated Microscopy ImagingAs the core technology platform, based on itsOptical Nonlinear EffectsA profound understanding, through precise light source control and high-throughput computing power, has overcome the sensitivity and speed limitations of traditional methods, thereby achieving a future-orientedNon-destructive, Non-invasive High-precision Quantitative Imaging Analysis of Substances. In addition, as a leading Chinese company that has achieved mass shipments in the field of advanced optics and microscopy technology, Suzhou Weibang Zhendian Optoelectronic Technology Co., Ltd. beganTo occupy a place in the ultra-high-end optical instrument market dominated by foreign countries.。

Suzhou Weibang Zhendian Optoelectronic Technology Co., Ltd. is a representative enterprise of Fengrui's investment in the intersection field of computing and optics. We look forward to Suzhou Weibang Zhendian Optoelectronic Technology Co., Ltd. continuing to rely on its advanced technology platform and innovation capabilities, constantly exploring, advancing, and breaking through in the field of optical technology to achieveFrom Biology to Medicine，From Clinical to IndustrialA comprehensive breakthrough.

/ Company Details /

Suzhou Weibang Zhendian Optoelectronic Technology Co., Ltd. is a company centered aroundMolecular Vibrational Spectroscopy TechnologyInnovation, committed to buildingHigh-End Chinese-Made Spectral Analysis and Imaging ProductsAndPrecision Medical Diagnosis PlatformHigh-tech enterprise.

Suzhou Weibang Zhendian Optoelectronic Technology Co., Ltd. was founded in 2017, encompassing Zhendian (Suzhou) Medical Technology Co., Ltd. and Weipeng (Suzhou) Medical Device Co., Ltd. The company has obtained the qualification of a national high-tech enterprise, the title of Leading Talent in Science and Technology of Suzhou Industrial Park, and the second prize in China's Medical Device Innovation and Entrepreneurship Competition.

The core team of the company inSpectral Technology, Optical Imaging, Photoelectric AnalysisWith many years of R&D accumulation in related fields, it possesses leading technological capabilities that are independently controlled on a global scale, with more than 10 core patents developed independently and 16 exclusively authorized patents from world-renowned research institutions.

The company currently has more than 1,000 square meters of R&D and production space, with a sound design development system and quality control system in place. It has obtained certifications for the medical device quality system and GMP system. (For details, see the report.)【Artery Network First Release】Suzhou Weibang Zhendian Optoelectronic Technology Co., Ltd. Completes Nearly RMB 100 Million in Series A+ Financing, Accelerating Market Commercialization and Iterative Development of Industrial Solutions）

▲Image Source: Hangkai Microelectronics Official Website

Hangkai MicroelectronicsRaised tens of millions of yuan in angel round financing,FREES FUND Exclusive Investment。

/ Investor Says /

Robotics IndustryIn progress toGeneral IntelligenceThe future exploration and advancement. The realization of the "cerebrum and cerebellum" functions in robots is inseparable from sensors acting as "senses" to perceive the surrounding environment and the working status of the robot. As the sensing device for the fundamental physical quantity of interaction—force—sensors are the hardware foundation for robots to achieve force feedback control capabilities. In the past, constrained by the sensing principles of traditional mechanical strain gauges, multi-dimensional force sensors hadLarge volume, process reliant on manual labor, and high costAnd other issues, which have slowed the penetration progress in the robotics industry.

Dr. GaiWith over 20 years of R&D experience in the sensor industry within the aerospace field. Hangkai Microelectronics not only achievedCost Reduction in the Design of Mechanical Six-Axis Force Sensors, and more based on the understanding of the design and manufacturing process of MEMS sensors, the MEMS process is implemented in a "chip-based" mannerReconstructed a new form of multi-dimensional force sensor。

We look forward to the Hangkai Microelectronics team advancing the chipization of force sensor tracks, and in the future, landing force sensor products with high automation processes, high integration, and high cost-effectiveness.Humanoid Robots, Intelligent Manufacturing, and Industrial EquipmentIn fields such as ..., advance the evolution of "force control" in various scenarios.

/ Company Details /

"Hangkai Microelectronics" was founded in October 2021, focusing onForce-related SensorThe company's products include silicon-based MEMS accelerometers, multi-dimensional force sensors (six-axis force sensors), etc.

At this stage, six-axis force sensors are also gradually being usedHumanoid RobotDuring the development and production process, itsAnkle and Wrist JointsAll need to be installed.Six-axis Force Sensor, to measure the load weight and ensure smooth control of the movement process, guaranteeing the overall system accuracy of the humanoid robot.

"Hangkai Microelectronics" hasMature silicon-based MEMS accelerometer design and process experience, the next step is to developMulti-axis Force Sensor, which combines metal-based sensors with silicon-based MEMS technology to develop compact, high-precision, and low-cost MEMS multi-axis force sensors suitable for micro-force, micro-size, and multi-sensor fusion intelligent force control systems. (For more details, see the report.)【36Kr Pro】"Hangkai Microelectronics" Secures Tens of Millions in Angel Financing, Funds to Be Used for R&D and Production of Multi-Axis Force Sensors | 36Kr Exclusive）

▲ Congratulations to XtalPi on its successful IPO:Frees Fund adheres to research-driven principles and learns investment from investing.

▲ Li Feng in Conversation with Ji Yu: Understanding NVIDIA, Deconstructing NVIDIA, Challenging NVIDIA

▲ The Road to Embodied Intelligence | PeakRidge Report 37

▲ Li Feng in Conversation with Zhang Wei, Founder of Zhuge Power: Humanoid? Robot?

▲ How Far is Embodied Intelligence from Reality: Hype, Bubble, Technological Frontier, Commercialization

▲ Four Financing News Arriving with Spring | FreeS Family Financing News Vol.18